{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:25:24Z","timestamp":1785813924225,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K17860"],"award-info":[{"award-number":["19K17860"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012832","name":"Okinaka Memorial Institute for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12185-021-03117-7","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T13:03:29Z","timestamp":1614690209000},"page":"642-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment-free remission and immunity in chronic myeloid leukemia"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":false,"given":"Hiroshi","family":"Ureshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"3117_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"3117_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.clml.2020.07.004","volume":"20","author":"H Ureshino","year":"2020","unstructured":"Ureshino H, Kamachi K, Kimura S. Surrogate markers for treatment-free remission in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:785\u201390.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3117_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"3117_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"3117_CR5","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528\u201335.","journal-title":"Lancet Haematol"},{"key":"3117_CR6","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","volume":"103","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103:1835\u201342.","journal-title":"Haematologica"},{"key":"3117_CR7","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7:e218\u201325.","journal-title":"Lancet Haematol"},{"key":"3117_CR8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525\u201331.","journal-title":"Leukemia"},{"key":"3117_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"3117_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44\u20139.","journal-title":"Science"},{"key":"3117_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1084\/jem.188.1.71","volume":"188","author":"DJD Sourdive","year":"1998","unstructured":"Sourdive DJD, Murali-Krishna K, Altman JD, Zajac AJ, Whitmire JK, Pannetier C, et al. Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med. 1998;188:71\u201382.","journal-title":"J Exp Med"},{"key":"3117_CR12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00018-012-0965-x","volume":"69","author":"D Zehn","year":"2012","unstructured":"Zehn D, King C, Bevan MJ, Palmer E. TCR signaling requirements for activating T cells and for generating memory. Cell Mol Life Sci. 2012;69:1565\u201375.","journal-title":"Cell Mol Life Sci"},{"key":"3117_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/cas.13430","volume":"109","author":"T Kumagai","year":"2018","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109:182\u201392.","journal-title":"Cancer Sci"},{"key":"3117_CR14","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1038\/bcj.2017.84","volume":"7","author":"M Matsushita","year":"2017","unstructured":"Matsushita M, Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, et al. CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. Blood Cancer J. 2017;7:e601\u20137.","journal-title":"Blood Cancer J"},{"key":"3117_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/1535-7163.MCT-20-0336","volume":"20","author":"H Ureshino","year":"2021","unstructured":"Ureshino H, Shindo T, Tanaka H, Saji H, Kimura S. HLA polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. Mol Cancer Ther. 2021;20:142\u20139.","journal-title":"Mol Cancer Ther"},{"key":"3117_CR16","first-page":"2935","volume":"15","author":"T Jo","year":"2018","unstructured":"Jo T, Noguchi K, Hayashi S, Irie S, Hayase R, Shioya H, et al. Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib. Oncol Lett. 2018;15:2935\u20138.","journal-title":"Oncol Lett"},{"key":"3117_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Sch\u00fctz","year":"2017","unstructured":"Sch\u00fctz C, Inselmann S, Sausslele S, Dietz CT, M\u00fcller MC, Eigendorff E, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31:829\u201336.","journal-title":"Leukemia"},{"key":"3117_CR18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","volume":"127","author":"H Nishikawa","year":"2010","unstructured":"Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759\u201367.","journal-title":"Int J Cancer"},{"key":"3117_CR19","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129:1166\u201376.","journal-title":"Blood"},{"key":"3117_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bjh.16718","volume":"191","author":"YD Irani","year":"2020","unstructured":"Irani YD, Hughes A, Clarson J, Kok CH, Shanmuganathan N, White DL, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020;191:433\u201341.","journal-title":"Br J Haematol"},{"key":"3117_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2005-05-1897","volume":"107","author":"BN Savani","year":"2006","unstructured":"Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2006;107:1688\u201395.","journal-title":"Blood"},{"key":"3117_CR22","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368\u201377.","journal-title":"Haematologica"},{"key":"3117_CR23","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Str\u00f6mberg U, Schlums H, Guilhot J, Br\u00fcck O, L\u00e4hteenm\u00e4ki H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108\u201316.","journal-title":"Leukemia"},{"key":"3117_CR24","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","volume":"126","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Tang C, Vidovic L, White DL, Branford S, Hughes TP, et al. KIR2DL5B genotype predicts outcomes in CML patients treated with response directed sequential imatinib\/nilotinib strategy. Blood. 2015;126:2720\u20133.","journal-title":"Blood"},{"key":"3117_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","volume":"6","author":"H Ureshino","year":"2018","unstructured":"Ureshino H, Shindo T, Kojima H, Kusunoki Y, Miyazaki Y, Tanaka H, et al. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res. 2018;6:745\u201354.","journal-title":"Cancer Immunol Res"},{"key":"3117_CR26","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","volume":"43","author":"G Caocci","year":"2015","unstructured":"Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, et al. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Exp Hematol. 2015;43:1015\u20138.","journal-title":"Exp Hematol"},{"key":"3117_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"},{"key":"3117_CR28","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532\u20139.","journal-title":"Blood"},{"key":"3117_CR29","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markev\u00e4rn B, Remes K, Stentoft J, Almqvist A, et al. Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118:3228\u201335.","journal-title":"Blood"},{"key":"3117_CR30","first-page":"e56","volume":"186","author":"DM Ross","year":"2019","unstructured":"Ross DM, Pagani IS, Irani YD, Clarson J, Leclercq T, Dang P, et al. Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. Br J Haematol. 2019;186:e56-60.","journal-title":"Br J Haematol"},{"key":"3117_CR31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772\u201382.","journal-title":"Blood"},{"key":"3117_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2019.1638210","volume":"8","author":"A Kreutzman","year":"2019","unstructured":"Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Lee Hee M, Janssen J, et al. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. OncoImmunol. 2019;8:1\u201313.","journal-title":"OncoImmunol"},{"key":"3117_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-22","volume":"9","author":"F Fei","year":"2010","unstructured":"Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, et al. Effects of nilotinib on regulatory T cells: the dose matters. Mol Cancer. 2010;9:1\u201310.","journal-title":"Mol Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03117-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03117-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03117-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T08:22:13Z","timestamp":1697962933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03117-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3117"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03117-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}